Merck’s Two-Drug HIV Therapy Shows Strong Phase 3 Efficacy
RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...
AI drug discovery artificial intelligence Autoimmune Disease biologics biopharma Biopharmaceuticals Biotechnology Bispecific Antibody Cancer Immunotherapy Cancer Research cancer therapy Cancer Treatment Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Drug Discovery EMA FDA fda approval FDA clearance Gene Therapy healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology Ophthalmology Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 Phase 3 trial Precision Medicine Precision Oncology rare disease Regenerative Medicine targeted therapy
RAHWAY, N.J. – October 15, 2025 — Merck (NYSE: MRK) announced new Phase 3 trial results for its investigational,...
Burlington, Massachusetts – October 15, 2025 – MilliporeSigma, the U.S. and Canada Life Science business of Merck KGaA, Darmstadt,...
NUTLEY, N.J., Oct. 2, 2025 — Eisai Inc. announced today the presentation of its expansive oncology portfolio at the...
RAHWAY, N.J., Sept. 30, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada, today...
RAHWAY, N.J. – September 20, 2025 — Merck (NYSE: MRK) announced that the U.S. Food and Drug Administration (FDA)...
BASKING RIDGE, N.J. and RAHWAY, N.J., September 15, 2025 – Daiichi Sankyo and Merck (known as MSD outside the...
RAHWAY, N.J. – September 11, 2025 – Merck (NYSE: MRK), known as MSD outside the United States and Canada,...
